HC Wainwright Issues Pessimistic Forecast for AGMB Earnings

AgomAb Therapeutics NV (NASDAQ:AGMB) – Analysts at HC Wainwright decreased their FY2026 earnings per share (EPS) estimates for AgomAb Therapeutics in a research note issued on Thursday, August 13th. HC Wainwright analyst P. Trucchio now forecasts that the company will earn ($1.96) per share for the year, down from their prior estimate of ($1.78). HC Wainwright currently has a “Buy” rating and a $35.00 target price on the stock. The consensus estimate for AgomAb Therapeutics’ current full-year earnings is ($1.77) per share. HC Wainwright also issued estimates for AgomAb Therapeutics’ FY2027 earnings at ($2.08) EPS, FY2028 earnings at ($1.80) EPS, FY2029 earnings at ($1.86) EPS and FY2030 earnings at ($1.83) EPS.

Several other equities research analysts also recently weighed in on the company. B. Riley Financial initiated coverage on AgomAb Therapeutics in a report on Thursday, July 23rd. They issued a “buy” rating and a $34.00 price target for the company. Wall Street Zen downgraded shares of AgomAb Therapeutics from a “hold” rating to a “sell” rating in a report on Saturday. Five investment analysts have rated the stock with a Buy rating and one has assigned a Hold rating to the company. According to data from MarketBeat, the company presently has an average rating of “Moderate Buy” and an average target price of $33.00.

AgomAb Therapeutics Trading Up 0.4%

Shares of AGMB stock opened at $13.73 on Monday. The stock’s fifty day simple moving average is $12.67. AgomAb Therapeutics has a 1-year low of $8.75 and a 1-year high of $17.82.

AgomAb Therapeutics (NASDAQ:AGMB) last issued its quarterly earnings data on Thursday, August 6th. The company reported ($0.46) EPS for the quarter.

AgomAb Therapeutics Company Profile

AgomAb Therapeutics (NASDAQ: AGMB) is a biotechnology company focused on the discovery and development of monoclonal antibody therapeutics. The company’s name and stated strategy center on the creation of agonist antibodies designed to modulate specific receptor pathways, with the aim of providing disease-modifying treatments where conventional approaches have been limited. AgomAb’s work spans early-stage discovery through translational development and regulatory-directed studies.

AgomAb’s activities include antibody engineering, target validation, and progression of programs through preclinical and, when applicable, clinical development milestones.